Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Medical Oncology · Anthracycline-Induced Cardiomyopathy

How Anthracyclines Affect Your Heart Cells

At a Glance

Anthracyclines can injure heart muscle cells by damaging DNA and mitochondria, reducing energy production and increasing oxidative stress. The risk may build with cumulative doses, so clinicians track total exposure and heart function.

To understand how anthracyclines affect the heart, it helps to distinguish between two different types of heart problems. Most people are familiar with “plumbing” issues, where arteries get blocked by plaque (ischemic heart disease), leading to a heart attack [1][2]. Anthracycline cardiotoxicity is different: it is a “muscle” or “pump” problem [3]. The medicine travels through the bloodstream and interacts directly with the individual cells that make your heart beat, known as cardiomyocytes [4][5].

The Role of TOP2B: An Unintended Target

The primary way anthracyclines kill cancer cells is by targeting an enzyme called topoisomerase II (TOP2), which helps cells manage their DNA during division [6]. Cancer cells have a version called TOP2-alpha. Unfortunately, your heart muscle cells contain a very similar version called TOP2-beta (TOP2B) [6][7].

When anthracyclines enter a heart cell, they latch onto TOP2B. This interaction causes “breaks” in the heart cell’s DNA [4]. Because heart muscle cells do not divide and replace themselves easily, this DNA damage triggers a series of events that can lead to cell exhaustion or even cell death [3][8].

Mitochondrial Dysfunction: Energy Factory Failure

Heart cells require a massive amount of constant energy to keep your heart beating 100,000 times a day. This energy is produced in “power plants” inside the cell called mitochondria [9][10].

Anthracyclines disrupt these power plants in several ways:

  • Energy Shortage: The drugs interfere with the cell’s ability to create ATP, the primary fuel for the heart [9].
  • Oxidative Stress: The interaction creates reactive oxygen species (ROS)—unstable molecules often called “free radicals” that bounce around inside the cell, damaging its delicate internal structures [4][3].
  • Failed Biogenesis: Because of the DNA damage mentioned above, the cell loses its “blueprints” to build new, healthy mitochondria to replace the old ones [7][9].

Emerging Research: Iron and Ferroptosis

Recent preclinical research has highlighted the role of iron in this process. Emerging evidence suggests anthracyclines can cause iron to accumulate inside the mitochondria, which reacts with oxygen to create a specific type of damage called lipid peroxidation (where fatty membranes begin to degrade) [11][12].

This can lead to a newly researched type of cell death called ferroptosis (iron-dependent death) [11][13]. While this is an important pathway in the laboratory, anthracycline cardiotoxicity is complex and multifactorial. This research does not mean that patients should alter their dietary iron or take iron supplements—always discuss supplements with your care team.

A Cumulative Process

Because this is a direct toxic effect on the muscle cells, the damage is often cumulative [5]. Each dose of chemotherapy carries a small risk of injuring a few more cells. Most people have enough “reserve” heart muscle that they do not notice any changes during treatment [14]. However, as the total amount of medicine (the cumulative dose) increases, the heart’s reserve can be used up, potentially leading to symptoms of heart failure [7][15]. This is why doctors track your total lifetime dose of these drugs so carefully.

Common questions in this guide

How do anthracyclines damage the heart?
Anthracyclines can directly injure heart muscle cells rather than blocking the arteries. They can affect TOP2B, damage cell DNA, disrupt mitochondria, and increase unstable molecules that harm the cell.
Why does the total anthracycline dose matter?
Heart-cell injury can accumulate with each dose. As the lifetime dose rises, the heart may have less reserve to maintain its pumping function, sometimes causing heart failure symptoms.
What is ferroptosis, and should I change my iron intake?
Ferroptosis is a proposed form of iron-dependent cell death being studied in anthracycline-related heart injury. It is mainly emerging laboratory research, so do not change your dietary iron or take iron supplements without your care team’s advice.
Can dexrazoxane or other medicines protect my heart during anthracycline treatment?
Dexrazoxane, ACE inhibitors, beta-blockers, and liposomal formulations may be considered for some treatment plans, but the best choice depends on the cancer treatment and individual heart risk. Ask your oncology and cardiology teams whether any option is appropriate.
How can I tell treatment fatigue from possible heart-related changes?
Fatigue can have many causes during cancer treatment, and it is not possible to determine the cause at home from fatigue alone. Report new or worsening fatigue or other possible heart-failure symptoms to your care team so they can assess your heart function.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does the drug dexrazoxane make sense for my specific treatment plan to help protect my heart's TOP2B enzymes?
  2. 2.Are there other 'muscle-protecting' medications, like ACE inhibitors or beta-blockers, that could help my heart's mitochondria stay healthy during treatment?
  3. 3.How does my cumulative dose of anthracyclines compare to the thresholds where heart muscle damage becomes more likely?
  4. 4.Would a liposomal version of this chemotherapy be an option for me to reduce direct exposure to my heart cells?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?

    Murabito A, Hirsch E, Ghigo A

    Frontiers in cardiovascular medicine 2020; (7()):35 doi:10.3389/fcvm.2020.00035.

    PMID: 32226791
  2. 2

    Mitochondrial Dysfunction in Cardiac Diseases: Insights into Pathophysiology and Clinical Outcomes.

    Ahmad SS, Ansari JA, Ansari TM, Zaidi SMH

    Current cardiology reviews 2026; (22(1)):e1573403X379197 doi:10.2174/011573403X379197250417061904.

    PMID: 40329726
  3. 3

    Molecular mechanisms of anthracycline cardiovascular toxicity.

    Narezkina A, Narayan HK, Zemljic-Harpf AE

    Clinical science (London, England : 1979) 2021; (135(10)):1311-1332 doi:10.1042/CS20200301.

    PMID: 34047339
  4. 4

    ANTHRACYCLINE-INDUCED CARDIOTOXICITY: MECHANISM AND PREVENTION.

    Yeh ETH, Chang HM

    Transactions of the American Clinical and Climatological Association 2025; (135()):184-195.

    PMID: 40771595
  5. 5

    Temporal Dynamics of Extracellular Matrix Remodeling in Anthracycline-Induced Cardiotoxicity.

    Meshrkey F, Ibrahim SY, Bagchi RA, Richardson WJ

    Cells 2025; (14(18)) doi:10.3390/cells14181471.

    PMID: 41002436
  6. 6

    Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.

    Jirkovský E, Jirkovská A, Bavlovič-Piskáčková H, et al.

    Circulation. Heart failure 2021; (14(11)):e008209 doi:10.1161/CIRCHEARTFAILURE.120.008209.

    PMID: 34551586
  7. 7

    Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.

    Henriksen PA

    Heart (British Cardiac Society) 2018; (104(12)):971-977 doi:10.1136/heartjnl-2017-312103.

    PMID: 29217634
  8. 8

    Novel Mechanisms of Anthracycline-Induced Cardiovascular Toxicity: A Focus on Thrombosis, Cardiac Atrophy, and Programmed Cell Death.

    Antoniak S, Phungphong S, Cheng Z, Jensen BC

    Frontiers in cardiovascular medicine 2021; (8()):817977 doi:10.3389/fcvm.2021.817977.

    PMID: 35111832
  9. 9

    Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy.

    Wallace KB, Sardão VA, Oliveira PJ

    Circulation research 2020; (126(7)):926-941 doi:10.1161/CIRCRESAHA.119.314681.

    PMID: 32213135
  10. 10

    Alteration of cardiac energetics and mitochondrial function in doxorubicin‑induced cardiotoxicity: Molecular mechanism and prospective implications (Review).

    Qing G, Huang C, Pei J, Peng B

    International journal of molecular medicine 2025; (56(5)).

    PMID: 40910252
  11. 11

    Ferroptosis as a target for protection against cardiomyopathy.

    Fang X, Wang H, Han D, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2019; (116(7)):2672-2680 doi:10.1073/pnas.1821022116.

    PMID: 30692261
  12. 12

    Doxorubicin-Induced Cardiotoxicity: Comprehensive Pathway Insights and Advanced Preclinical Therapeutics.

    Sharma S, Parashar M, Lal K, et al.

    Journal of applied toxicology : JAT 2026; (46(6)):1801-1837 doi:10.1002/jat.70131.

    PMID: 41808568
  13. 13

    Doxorubicin-induced cardiotoxicity: Is ferroptosis the primary driver or a downstream amplifier?

    Goswami Y, Sharma N, Navik U

    EXCLI journal 2026; (25()):974-990 doi:10.17179/excli2026-9516.

    PMID: 42517079
  14. 14

    The Role of Biomarkers in Cardio-Oncology.

    Ananthan K, Lyon AR

    Journal of cardiovascular translational research 2020; (13(3)):431-450 doi:10.1007/s12265-020-10042-3.

    PMID: 32642841
  15. 15

    Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

    Cardinale D, Colombo A, Bacchiani G, et al.

    Circulation 2015; (131(22)):1981-8 doi:10.1161/CIRCULATIONAHA.114.013777.

    PMID: 25948538

This page explains how anthracycline medicines can affect heart muscle for educational purposes and does not constitute medical advice. Discuss your cumulative dose, heart monitoring, and possible protective medicines with your oncology and cardiology teams.

Get notified when new evidence is published on Cardiomyopathy due to anthracyclines.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.